# US 2024/0201196 A1 · Non-covalent halotag ligands

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0201196 A1
- Document ID: US20240201196A1
- Status: Published application
- Kind: A1
- Application number: 18/554,819
- Filed: 2022-05-02
- Published: 2024-06-20
- Earliest claimed: 2021-04-30
- Assignees: Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V.
- Applicants: Max-Planck-Gesellschaft Zur FöRderung Der Wissenschaften E. V.
- Inventors: Kai JOHNSSON; Julien HIBLOT; Julian KOMPA
- Web page: https://patentgrep.com/patent/US20240201196A1

## CPC

- C09B 11/24: Phthaleins containing amino groups {; Phthalanes; Fluoranes; Phthalides; Rhodamine dyes; Phthaleins having heterocyclic aryl rings; Lactone or lactame forms of triarylmethane dyes}
- G01N 33/581: {with enzyme label (including co-enzymes, co-factors, enzyme inhibitors or substrates)}
- C07K 1/13: Labelling of peptides
- C07K 14/001: {by chemical synthesis}
- C12N 9/14: Hydrolases (3)
- C12Y 308/01005: Haloalkane dehalogenase (3.8.1.5)
- G01N 33/582: {with fluorescent label}
- G01N 2333/90241: acting on single donors with incorporation of molecular oxygen, i.e. oxygenases (1.13)
- C09B: ORGANIC DYES OR CLOSELY-RELATED COMPOUNDS FOR PRODUCING DYES {, e.g. PIGMENTS}; MORDANTS; LAKES (fermentation or enzyme using processes to synthesise a desired chemical compound C12P)
- G01N: INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES (measuring or testing apparatus or processes other than immunoassay, involving enzymes or microorganisms C12M, C12Q)
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- C12Y: ENZYMES

## Abstract

A first aspect of the invention relates to a non-covalently-HaloTag-binding compound characterized by the general formula D-L-T (I), wherein D is or comprises a functional moiety Z, particularly a fluorescent dye, or D is a linkable moiety (i.e. a moiety that can be coupled to other functional groups), L is a linear linker of 10-15 atoms in length, and T is a moiety selected from the group comprising methylamine, methylsulfonamide, acetamide, or their respective fluorinated analogues, azide, or hydroxyl. Another aspect of the invention relates to a HaloTag variant wherein position D106 of the HaloTag7 sequence is exchanged for a proteinogenic amino acid different from D. The variant has a different binding specificity for HaloTag substrates compared to the non-variant Halotag polypeptide. Yet another aspect of the invention relates to kits comprising polypeptides or nucleic acids and the non-covalently-HaloTag-binding compound according to the invention.

## Claims

### Claim 1

A non-covalently-HaloTag-binding compound characterized by the general formula (I)
D-L-T (I), wherein
a. D is or comprises a functional moiety Z selected from
an organic dye moiety characterized by a molecular mass of between 300 g/mol and 1300 g/mol, particularly a fluorescent organic dye moiety;
an affinity purification ligand,
a pharmaceutical drug or a pharmaceutical drug candidate,
an oligopeptide or a polypeptide,
a nanoparticle,
a solid surface or a matrix polymer,
a nucleic acid oligomer,
a carbohydrate,
a lipid,
a spectroscopic probe,
a sensor, particularly a fluorescent sensor,
a natural product, and
a synthetic ligand binding to a biomolecule with an affinity of at least 100 μM,
or
b. D is a linkable moiety selected from
an unprotected or protected amine moiety,
a sulfonamide moiety,
an N3 moiety,
an alkyne moiety,
a carboxylic acid or an activated form of a carboxylic acid, particularly an N-hydroxysuccinimide moiety,
an ester moiety,
an aldehyde,
a thiol, and
an isothiocyanate;
L is a linear linker of 10-15 atoms in length, particularly wherein L is 10-11 atoms in length,
wherein L comprises, particularly L essentially consists of, alkyl, trans-alkylene, and/or ether moieties and optionally one or several methyl substituents,
particularly L is an unbranched linker that does not comprise methyl substituents;
T is a moiety selected from the group comprising methylamine, monofluormethylamine, difluormethylamine, trifluormethylamine, methylsulfonamide, monofluormethylsulfonamide, difluormethylsulfonamide, trifluormethylsulfonamide, azide, acetamide, monofluoracetamide, difluoracetamide, and trifluoracetamide;
particularly T is a moiety selected from the group comprising methylamine, trifluormethylsulfonamide and methylsulfonamide.

### Claim 2

A non-covalently-HaloTag-binding compound characterized by the general formula (I)
D-L-T (I), wherein
a. D is or comprises a functional moiety Z selected from
an organic dye moiety characterized by a molecular mass of between 300 g/mol and 1300 g/mol, particularly a fluorescent organic dye moiety;
an affinity purification ligand,
a pharmaceutical drug or a pharmaceutical drug candidate,
an oligopeptide or a polypeptide,
a nanoparticle,
a solid surface or a matrix polymer,
a nucleic acid oligomer,
a carbohydrate, and
a lipid,
a spectroscopic probe,
a fluorescent sensor,
a natural product,
a synthetic ligand binding to a biomolecule with an affinity of at least 100 μM,
L is a linear linker of 10-15 atoms in length, particularly wherein L is 10-11 atoms in length,
wherein L comprises, particularly L essentially consists of, alkyl, trans-alkylene, and/or ether moieties and optionally one or several methyl substituents,
particularly L is an unbranched linker that does not comprise methyl substituents;
T is a moiety selected from the group comprising methylamine, monofluormethylamine, difluormethylamine, trifluormethylamine, methylsulfonamide, monofluormethylsulfonamide, difluormethylsulfonamide, trifluormethylsulfonamide, azide, acetamide, monofluoracetamide, difluoracetamide, and trifluoracetamide, and hydroxyl,
particularly T is a moiety selected from the group comprising methylamine, methylsulfonamide, trifluormethylsulfonamide and hydroxyl.

### Claim 3 (depends on 2)

The non-covalently-HaloTag-binding compound according to claim 2, wherein T is hydroxyl.

### Claim 4 (depends on 1)

The compound according to claim 1, wherein D comprises a linking moiety X which connects the functional moiety Z to L, particularly wherein X is selected from an amide, a secondary amine, a 1,2,3-triazole, an ester, a sulfonamide, an ether, a thioether, a thiourea, an urea, and a carbamate.

### Claim 5 (depends on 1)

The compound according to claim 1, wherein L is a linear unbranched alkyl chain, comprising 1, 2, or 3 moieties independently selected from ether and trans-alkylene.

### Claim 6 (depends on 1)

The compound according to claim 1, wherein the compound is characterized by the one of the general formulas (II), (III), (IV), (V) or (VI), particularly of the general formula (II),
wherein n is an integer selected from 1, 2, 3, and 4, particularly n is 1 or 2, more particularly n is 1.

### Claim 7 (depends on 1)

The compound according to claim 1, wherein Z is a fluorophore, particularly a fluorophore selected from a rhodamine, a silicon rhodamine, a fluorescein, a Janelia Fluor dye, an olefinic silicon rhodamine derivative with an exocyclic double bond, a MaP dye, a carbopyronine, a carbocyanine (particularly a Cy3, or a Cy5 dye), a pyrene, a Bodipy fluorophore, a coumarine, a rhodol, and an Alexa dye.

### Claim 8 (depends on 1)

The compound according to claim 1, wherein Z is of the general formula (VII) or of the general formula (VIII)
wherein
V is selected from —C(═O)W, —CH3, and —CH2OH, wherein W is OH or NRW1RW2 with RW1 and RW2 being independently selected from H, unsubstituted or amino- or hydroxy-substituted C1-C8 alkyl, CN, SO2NRS1RS2 and SO2RS with RS being unsubstituted or amino- or hydroxy-substituted C1-C6 alkyl, and with RS1 and RS2 being independently selected from H and unsubstituted or amino- or hydroxy-substituted C1-C6 alkyl;
R1, R2, R3, and R4 are independently selected from H and an unsubstituted or hydroxy-, amino-, halogen-, and/or carboxy-substituted hydrocarbon moiety selected from C1-C8 alkyl, C3-C8 cycloalkyl, C1-C4 acyl, C7-C12 alkylaryl, an unsubstituted phenyl or a phenyl substituted by any one or several of the following substituents:
unsubstituted C1-C4 alkyl, halogen, C1-C4 oxyalkyl, COOH, COORC, CONRC2, with RC being selected from H and unsubstituted or amino- or hydroxy-substituted C1-C8 alkyl;
or R1, R2, R3, and/or R4 form a ring structure as described below;
R5 is selected from an amine, carbonyl, ester, amide, sulfonamide, and a hydrocarbon moiety selected from C1-C8 alkyl, C3-C8 cycloalkyl, C7-C12 alkylaryl, and phenyl,
wherein R5 is unsubstituted or hydroxy-, amino-, halogen-, and/or carboxy-substituted;
n is an integer selected from 0, 1, and 2;
R6 is selected from an amine, carbonyl, ester, amide, sulfonamide, and a hydrocarbon moiety selected from C1-C8 alkyl, C3-C8 cycloalkyl, C7-C12 alkylaryl, and phenyl,
wherein R6 is unsubstituted or hydroxy-, amino-, halogen-, and/or carboxy-substituted;
X is selected from O, S, Se, TeO, PORX, POORX, SO2, NRX, CRX2, SiRX2, GeRX2, and SnRX2, with each RX being independently selected from H and an unsubstituted or substituted (particularly unsubstituted or hydroxy-, amino-, halogen-, and/or carboxy-substituted) moiety selected from C1-C12 alkyl, C3-C8 cycloalkyl, C2-C12 alkenyl, C2-C12 alkynyl, C7-C12 alkylaryl, phenyl and 5- or 6-membered heteroaryl, or two RX moieties form a four-, five-, six- or seven-membered unsubstituted or amino-, hydroxy- and/or halogen substituted alkyl ring;
particularly X is selected from O, CRX2, and SiRX2;
Y is OH or NRY1RY2,
Z is O or N+RY1RY2
with
RY1, and RY2 each independently selected from H, an unsubstituted or hydroxy-, amino-, halogen-, and/or carboxy-substituted hydrocarbon moiety selected from C1-C8 alkyl, C3-C8 cycloalkyl, C1-C4 acyl, C7-C12 alkylaryl, an unsubstituted phenyl or a phenyl substituted by any one or several of the following substituents: unsubstituted C1-C4 alkyl, halogen, C1-C4 oxyalkyl, COOH, COORYC, CONRYC2, with RYC being selected from H and unsubstituted or amino- or hydroxy-substituted C1-C8 alkyl; or
RY1 and RY2 together are a C3-C6 unsubstituted or hydroxy-, amino-, halogen-, alkoxy- and/or carboxy-substituted alkyl forming a 4-7-membered ring structure with Y; or
one of RY1 and RY2, or both RY1 and RY2, together with R1 and/or R2, and/or R3 and/or R4, respectively, form an unsubstituted or hydroxy-, amino-, halogen-, carboxy- and/or aryl-substituted 4-7-membered alkyl or alkylene ring;
wherein Z is connected to L via a substituent selected from R1, R2, R3, R4, R5, R6, Y, Z and V.

### Claim 9 (depends on 1)

A kit comprising
a. a catalytically functional HaloTag polypeptide, wherein optionally said HaloTag polypeptide is attached to a polypeptide of interest;
or
an expression vector encoding said catalytically functional HaloTag polypeptide;
and the kit further comprising a compound according to claim 1;
or
b. a D106 mutant HaloTag polypeptide, wherein position D106 of the HaloTag7 sequence (position 103 designated as X in SEQ ID No 001) is exchanged for a proteinogenic amino acid different from D,
particularly wherein the mutant HaloTag polypeptide comprises a mutation selected from D106A, D106G, and D106T, more particularly wherein the mutant HaloTag polypeptide comprises a D106A mutation,
or a D106 mutant HaloTag polypeptide, wherein, in a HaloTag polypeptide sequence homologous to HaloTag7, at a position homologous to D106 of HaloTag7, D is exchanged for a proteinogenic amino acid different from D,
particularly wherein said position is changed to A, G or T, more particularly wherein said position is changed to A,
wherein optionally said D106 mutant HaloTag polypeptide is attached to a polypeptide of interest;
or
an expression vector encoding said D106 mutant HaloTag polypeptide;
and the kit further comprising a compound characterized by the general formula (I)
D-L-T (I), wherein
D is or comprises a functional moiety Z selected from
an organic dye moiety characterized by a molecular mass of between 300 g/mol and 1300 g/mol, particularly a fluorescent organic dye moiety;
an affinity purification ligand,
a pharmaceutical drug or a pharmaceutical drug candidate,
an oligopeptide or a polypeptide,
a nanoparticle,
a solid surface or a matrix polymer,
a nucleic acid oligomer,
a carbohydrate, and
a lipid,
a spectroscopic probe,
a fluorescent sensor,
a natural product,
a synthetic ligand binding to a biomolecule with an affinity of at least 100 μM,
L is a linear linker of 10-15 atoms in length, particularly wherein L is 10-11 atoms in length,
wherein L comprises, particularly L essentially consists of, alkyl, trans-alkylene, and/or ether moieties and optionally one or several methyl substituents,
particularly L is an unbranched linker that does not comprise methyl substituents;
T is a moiety selected from the group comprising methylamine, monofluormethylamine, difluormethylamine, trifluormethylamine, methylsulfonamide, monofluormethylsulfonamide, difluormethylsulfonamide, trifluormethylsulfonamide, azide, acetamide, monofluoracetamide, difluoracetamide, and trifluoracetamide, and hydroxyl,
particularly T is a hydroxyl.

### Claim 10 (depends on 1)

A method for binding a HaloTag polypeptide in a sample, said method comprising the steps of:
a. providing an aqueous sample comprising a HaloTag polypeptide;
b. contacting the sample with a compound comprising a fluorescent organic dye moiety according to claim 1;
c. illuminating the sample with light of an excitation wavelength appropriate for exciting said fluorescent organic dye moiety, and recording light emitted from said sample, particularly at an appropriate emission wavelength 2, more particularly a λ close to a maximum of the emission spectrum of 400-800 nm,
d. optionally repeating step c.

### Claim 11 (depends on 1)

A method for labelling a HaloTag polypeptide in a sample, said method comprising the steps of:
a. providing an aqueous sample comprising a HaloTag polypeptide attached to a luciferase;
b. contacting the sample with a compound comprising a fluorescent organic dye moiety according to claim 1;
c. contacting the sample with a luciferase substrate and recording light emitted from said sample, particularly at an appropriate emission wavelength λ, more particularly a λ close to a maximum of the emission spectrum of 400-800 nm;
d. optionally repeating step c.

### Claim 12 (depends on 10)

The method according to claim 10, wherein a first and a second HaloTag polypeptide are specifically labelled,
wherein the first HaloTag polypeptide is a wildtype polypeptide and wherein the second HaloTag polypeptide is a HaloTag polypeptide mutant, wherein D106 of HaloTag7 or the analogous D of a different HaloTag, is exchanged for a different proteinogenic amino acid,
particularly wherein the second HaloTag polypeptide comprises a mutation selected from D106A, D106G, and D106T, or the analogous mutation of D, more particularly wherein the second HaloTag polypeptide comprises a D106A mutation, or the analogous mutation of D, and
wherein a first and a second compound comprising a first fluorescent organic dye moiety and a second fluorescent organic dye, respectively, are employed,
wherein for the first compound T is a moiety selected the group comprising of methylamine, methylsulfonamide, monofluormethylsulfonamide, difluormethylsulfonamide, trifluormethylsulfonamide, azide, and acetamide, monofluoracetamide, difluoracetamide, and trifluoracetamide,
particularly wherein T is selected from methylamine, methylsulfonamide, and trifluormethylsulfonamide,
and
wherein for the second compound T is OH, and
wherein the emission wavelength of the first fluorescent organic dye moiety is different from the emission wavelength of the second fluorescent organic dye moiety.

### Claim 13

A D106 mutant HaloTag polypeptide, wherein, in a HaloTag7 polypeptide sequence or a HaloTag polypeptide sequence homologous to HaloTag7, at position D106 of HaloTag7 or at a position homologous to D106 of HaloTag7, D is exchanged for a proteinogenic amino acid different from D,
particularly wherein said position is changed to G, A, V, I, L, C, S, T, N, or E,
more particularly wherein said position is changed to A, G or T, even more particularly wherein said position is changed to A,

### Claim 14 (depends on 13)

The D106 mutant HaloTag polypeptide according to claim 13 comprising or essentially consisting of a sequence selected from SEQ ID NO 001 to SEQ ID NO 007,
wherein X is selected from any proteinogenic amino acid except D,
particularly wherein X is selected from G, A, V, I, L, C, S, T, N, and E, more particularly wherein X is selected from A, G, and T, most particularly wherein X is A.

### Claim 15 (depends on 13)

A nucleic acid sequence encoding the D106 mutant polypeptide according to claim 13.
